Maximum Dose and Titration Guidelines for Ramipril
Indication‑Specific Maximum Doses
- For patients with heart failure (including post‑myocardial infarction), the recommended maximum dose is 10 mg once daily (or 5 mg twice daily)【1】.
- For patients with hypertension, the recommended maximum dose is 20 mg per day, given as a single dose or divided into two equal doses【1】【2】.
Initiation and Titration Strategy
- Start ramipril at 2.5 mg once daily for both hypertension and heart failure【1】.
- Double the dose every 2 weeks if the patient tolerates the medication, progressing through 2.5 mg → 5 mg → 10 mg once daily (or 5 mg twice daily for heart failure)【1】.
- Systolic blood pressure < 80 mmHg is a contraindication to further dose escalation【1】.
- Asymptomatic hypotension alone does not require dose reduction; dose adjustment is needed only if symptoms accompany the low pressure【1】.
Evidence Supporting Target Doses
- The ATLAS trial in heart failure showed that higher ACE‑inhibitor doses reduced the composite endpoint of death or hospital admission compared with lower doses, justifying titration to target doses【1】.
- The 2017 ACC/AHA/HFSA guidelines explicitly list ramipril’s target dose as 10 mg once daily for heart failure, based on the ATLAS evidence【2】.
Monitoring and Safety Thresholds
- Serum potassium > 5.5 mmol/L → halve the current ramipril dose【3】.
- Serum potassium > 6.0 mmol/L → discontinue ramipril immediately【3】.
- Serum creatinine rise to 3.0–3.5 mg/dL → halve the dose【3】.
- Serum creatinine > 3.5 mg/dL or a doubling from baseline → stop ramipril and obtain specialist input【3】.
- eGFR 20–25 mL/min/1.73 m² → halve the dose【3】.
- eGFR < 20 mL/min/1.73 m² → discontinue ramipril【3】.
- An acceptable rise in creatinine is up to 50 % above baseline or to 3 mg/dL (266 µmol/L), whichever is greater; modest increases should not trigger premature discontinuation【1】.
Drug Interaction Precautions
- Do not combine ramipril with ARBs or direct renin inhibitors – this combination increases harm without added benefit【3】.
- Avoid concomitant NSAIDs (including over‑the‑counter products) because they raise the risk of renal dysfunction and hyperkalemia【3】.
- Do not routinely add potassium supplements or potassium‑sparing diuretics unless specifically indicated, due to the risk of hyperkalemia【3】.
Monitoring Schedule During Titration
- Check serum creatinine, potassium, and blood pressure 1–2 weeks after each dose increase【3】.
- After reaching the maintenance dose, monitor at 1, 3, and 6 months, then at least every 4 months thereafter【3】.